Hyperglycemic hyperosmolar syndrome caused by steroid therapy in a patient with lupus nephritis

Journal of Korean Medical Science

Volumn 26, Issue 3, 2011, Pages 447-449

  Kang, Seok Hui ^a   Lee, Ja Young ^a   Park, Hoon Suk ^a   Sun, In O ^a   Choi, Sun Ryoung ^a   Chung, Byung Ha ^a   Choi, Bum Soon ^a   Yang, Chul Woo ^a   Kim, Yong Soo ^a   Park, Cheol Whee ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Hyperglycemic hyperosmolar syndrome; Lupus nephritis; Seizures; Steroids

Indexed keywords

INSULIN; PREDNISOLONE;

ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; EDEMA; FEMALE; HUMAN; HYPERGLYCEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; MIDDLE AGED; MYOCLONUS EPILEPSY;

EDEMA; EPILEPSIES, MYOCLONIC; FEMALE; HUMANS; HYPERGLYCEMIA; IMMUNOSUPPRESSION; INSULIN; LUPUS NEPHRITIS; MIDDLE AGED; PREDNISOLONE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 79953737913     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2011.26.3.447     Document Type: Article

References (16)

1. Appenzeller S, Cendes F, Costallat LT. Epileptic seizures in systemic lupus erythematosus. Neurology 2004; 63: 1808-12.
2. Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med 1996; 156: 1337-44.
3. Sanna G, Bertolaccini ML, Mathieu A. Central nervous system lupus: a clinical approach to therapy. Lupus 2003; 12: 935-42.
4. Kim BW, Kim JG, Ha SW, Lee HJ, Han JH, Jung SW, Nam JH, Park SH, Lee SH. Clinical manifestation and prognostic factors in nonketotic hyperosmolar coma. J Korean Diabetes Assoc 1999; 23: 575-84.
5. Rosenbloom AL. Hyperglycemic hyperosmolar state: an emerging pediatric problem. J Pediatr 2010; 156: 180-4.
6. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
7. Markowitz GS, D'Agati VD. Classification of lupus nephritis. Curr Opin Nephrol Hypertens 2009; 18: 220-5.
8. Wong KL, Woo EK, Yu YL, Wong RW. Neurological manifestations of systemic lupus erythematosus: a prospective study. Q J Med 1991; 81: 857-70.
9. Rabbani MA, Habib HB, Islam M, Ahmad B, Majid S, Saeed W, Shah SM, Ahmad A. Survival analysis and prognostic indicators of systemic lupus erythematosus in Pakistani patients. Lupus 2009; 18: 848-55.
10. Park SY, Kim SY, Kim DI, Kim HS, Yang SJ, Park JR, Kim DJ, Yoo HJ, Kwon SB, Baik SH. A case of hyperglycemic hyperosmolar syndrome induced by steroid treatment for idiopathic thrombocytopenic purpura. J Korean Diabetes Assoc 2005; 29: 571-3.
11. Shin MJ, Kim YO, Park JM, Bok HJ, Song KH, Yoon SA, Bang BK. Diabetic ketoacidosis after steroid administration for minimal change disease. Korean J Nephrol 1999; 18: 194-7.
12. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 23-43.
13. Van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009; 39: 81-93.
14. Simmons PS, Miles JM, Gerich JE, Haymond MW. Increased proteolysis. An effect of increases in plasma cortisol within the physiologic range. J Clin Invest 1984; 73: 412-20.
15. Pyörälä K, Suhonen O, Pentikäinan P. Steroid therapy and hyperosmolar non-ketotic coma. Lancet 1968; 1: 596-7.
16. Milionis HJ, Elisaf MS. Therapeutic management of hyperglycaemic hyperosmolar syndrome. Expert Opin Pharmacother 2005; 6: 1841-9.